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ROR Binds to E2F1 To Inhibit Cell Proliferation and Regulate
Mammary Gland Branching Morphogenesis
Gaofeng Xiong,a Ren Xua,b
Markey Cancer Centera and Department of Pharmacology and Nutritional Sciences,b University of Kentucky, Lexington, Kentucky, USA
Retinoic acid receptor-related orphan nuclear receptor alpha (ROR) is a potent tumor suppressor that reduces cell prolifera-
tion and inhibits tumor growth. However, the molecular mechanism by which it inhibits cell proliferation remains unknown.
We demonstrate a noncanonical nuclear receptor pathway in which ROR binds to E2F1 to inhibit cell cycle progression. We
showed that ROR bound to the heptad repeat and marked box region of E2F1 and suppressed E2F1-regulated transcription in
epithelial cells. Binding of ROR inhibited E2F1 acetylation and its DNA-binding activity by recruiting histone deacetylase 1
(HDAC1) to the protein complexes. Knockdown of HDAC1 or inhibition of HDAC activity at least partially rescued transcrip-
tion factor activity of E2F1 that was repressed by ROR. Importantly, ROR levels were increased in mammary ducts compared
to terminal end buds and inversely correlated with expression of E2F1 target genes and cell proliferation. Silencing ROR in
mammary epithelial cells significantly enhanced cell proliferation in the ductal epithelial cells and promoted side branching of
the mammary ducts. These results reveal a novel link between ROR and E2F1 in regulating cell cycle progression and mam-
mary tissue morphogenesis.
Nuclear receptors, a family of ligand-dependent transcriptionfactors, regulate gene expression by directly binding to the cis
response elements in the regulatory regions (1, 2). Retinoic acid
receptor-related orphan nuclear receptor alpha (ROR) is an or-
phan nuclear receptor and plays critical roles in many physiolog-
ical processes, including cell differentiation, metabolism, inflam-
mation, transformation, and circadian rhythm (3–11). The
canonical way that ROR regulates gene expression is through
ROR response elements in the regulatory regions of the target
genes (12, 13). ROR recruits a number of transcriptional coacti-
vators and corepressors to the target genes, including steroid re-
ceptor coactivator 1 (14) and p300 (15), nuclear receptor core-
pressor, and silencing mediator for retinoic acid and thyroid
hormone receptors (16). These transcriptional cofactors modu-
late the chromatin structure to induce or repress transcription.
Unlike the canonical pathway of nuclear receptor to regulate gene
expression, a number of recent studies show that ROR acts as a
transcriptional cofactor, binding to -catenin or p53 to regulate
target gene expression or modulate protein stability (7, 17).
Spatial and temporal regulation of cell proliferation is crucial
for normal tissue development and maintenance of the differen-
tiated state (18). For instance, mammary epithelial cells in the
mature ducts remain growth arrested, while cells in terminal end
buds are highly proliferative (19, 20). The different cell prolifera-
tion status in terminal end buds and ducts is important for mam-
mary gland branching morphogenesis and maintenance of the
ductal structure (21, 22). Enhancing cell proliferation in mam-
mary epithelial cells in the long run is sufficient to induce tumor-
igenesis (23, 24). We and others have shown that ROR expres-
sion is significantly downregulated during tumor development
and progression (7, 25), and exogenous ROR reduces cell prolif-
eration and inhibits tumor growth. But the molecular mechanism
by which ROR inhibits cell proliferation remains to be deter-
mined.
Cell proliferation is controlled by a series of cell cycle regula-
tors, such as transcription factor E2Fs, cyclin E, cyclin-dependent
kinases, and cell cycle brakes pRB and p27 (26–31). E2F1 is a
member of the E2F transcription factor family and plays impor-
tant roles in regulating G1/S transition, DNA synthesis, and apop-
tosis (32–35). E2F1 activity is regulated by a number of proteins
through protein-protein interaction (36–38). For example, bind-
ing of pRb inhibits E2F1 activity at G1 phase, and phosphorylation
of pRB releases it from E2F1 and leads to E2F1 activation (39).
E2F1 activity is also regulated by a number of covalent modifica-
tions, such as acetylation and phosphorylation (40, 41). Acetyla-
tion of lysine residues 117, 120, and 125 by the acetyltransferase
complex CBP/p/CAF enhances E2F1 DNA binding ability and sta-
bilizes E2F1 (41).
Using gene expression profile analysis, we showed that tran-
scription of E2F1 target genes was suppressed by ROR. Coim-
munoprecipitation (co-IP) and in vitro binding data demon-
strated that ROR bound to E2F1 and enhanced the interaction
between E2F1 and histone deacetylase 1 (HDAC1), which, in turn,
reduced E2F1 acetylation and inhibited its DNA-binding activity.
Importantly, high levels of ROR were associated with reduced
cell proliferation and repression of E2F1 target genes during
mammary branch morphogenesis. Silencing ROR in the mam-
mary epithelial cells enhanced cell proliferation in the ductal epi-
thelial cells and promoted side branching. These results identified
a noncanonical pathway of ROR to regulate gene expression and
mammary gland development, in which ROR binds to E2F1 to
inhibit E2F1-dependent cell cycle progression.
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MATERIALS AND METHODS
Antibodies and reagents. The 5-ethynyl-2=-deoxyuridine (EdU) staining
kit was from Invitrogen. Matrigel (laminin-rich extracellular matrix
[lrECM]) and type I collagen were from BD Bioscience. ROR cDNA was
purchased from Open Biosystems. E2F1 and DP1 cDNA clones were pur-
chased from Addgene. E2F1-Luc luciferase reporter vector was purchased
from Signosis, Inc. Plasmids carrying short hairpin RNA (shRNA) against
ROR (shROR plasmids) and shHDAC1 plasmids (a kind gift from
Zhou P. Binhua) were purchased from Sigma. HDAC inhibitor trichosta-
tin A (TSA) was purchased from Sigma. Antibodies against the following
antibodies were obtained: ROR, E2F1, and lamin A/C (Santa Cruz); Flag
(Sigma); Ki67 (Vector Laboratories); acetyllysine (Millipore); and
HDAC1 (Affinity BioReagents).
Cell culture and virus preparation. HMT-3522 S1 cells (hereafter
referred to as S1 cells; a kind gift from Mina J. Bissell) were maintained in
Dulbecco modified Eagle medium (DMEM)–F-12 medium containing
insulin at 2.5  107 g/ml, transferrin at 1.0  105 g/ml, sodium selenite
at 2.6  109 g/ml, 1.0  1010 M estradiol, 1.4  106 M hydrocorti-
sone, prolactin at 5.0  106 g/ml, and epidermal growth factor (EGF)
at 1.0  108 ng/ml. MDA-MB 231 cells (ATCC) were propagated in
DMEM–F-12 (Sigma) with 10% fetal bovine serum (Invitrogen).
MDA-MB 157 cells (ATCC) were propagated in DMEM (Sigma) with
10% fetal bovine serum (Invitrogen). Three-dimensional (3D) lrECM
on-top cultures were prepared by trypsinization of cells from tissue cul-
ture flasks, seeding of single cells on top of Engelbreth-Holm-Swarm
(EHS) tumor extract (Matrigel; BD Biosciences), and addition of medium
containing 5% EHS. MDA-MB 157 cells and MDA-MB 231 cells were
seeded at 1.4  104 per cm2. MDA-MB 157 cells and MDA-MB 231 cells
were maintained in H14 medium with 1% fetal bovine serum.
Flag-tagged ROR cDNA was cloned into plasmid pCDH1 and gen-
erated expression vector pCDH1-RORl-Flag. HEK293 FT cells were
transfected with pCDH1 or shRNA vector (Sigma) plus packaging len-
tivector using Lipofectamine (Invitrogen). Cancer cells were infected with
lentivirus and selected by puromycin 48 h after infection.
Microarray analysis. Control and ROR-expressing MDA-MB 231
and MDA-MB 157 cells were isolated from 3D cultures with phosphate-
buffered saline (PBS)-EDTA (5 mM EDTA, 1 mM NaVO4, 1.5 mM NaF in
PBS) on ice as previously described (42). Purified total cellular RNA was
extracted using an RNeasy minikit with on-column DNase digestion
(Qiagen). RNA was quantified by measuring optical density at 260 nm,
and quality was verified by agarose gel electrophoresis. Affymetrix mi-
croarray analysis was performed using the Affymetrix HuGene-1.0 high-
throughput array (HTA) GeneChip system. Preprocessing, normaliza-
tion, and filtering were performed using R Bioconductor (43). Gene
set enrichment analysis was performed with GSEA v2.07 (http://www
.broadinstitute.org/gsea/index.jsp) (44). E2F1 target gene expression lev-
els in terminal end buds and mammary ducts were derived from a pub-
lished microarray data set (Gene Expression Omnibus accession number
GSE2988). Unsupervised hierarchical clustering analysis was performed
with Cluster (uncentered correlation, average linkage), and results were
visualized with TreeView (http://www.eisenlab.org/eisen/?page_id42).
Luciferase reporter assay. A luciferase reporter vector containing four
E2F response elements (TTTCGCGC) was purchased from Signosis.
MDA-MB 231 cells were transfected with pCDNA plus pE2F1-Luc lucif-
erase vector (1:5). A luciferase vector pE2F1-Luc stable expression cell
clone was selected by G418 (8.0  104 g/ml) treatment. Cell lysates were
collected for the luciferase assay 48 h after infection with pCDH1-RORl-
Flag.
Immunohistochemistry. Mouse mammary gland sections and xeno-
graft tumor sections were deparaffinized and hydrated from xylene, 100%
ethanol, 95% ethanol, 85% ethanol, and 70% ethanol to PBS solution.
Endogenous peroxidase was blocked by incubation with 3% H2O2 for 20
min. At the antigen retrieval step, slides were steamed in citrate sodium
buffer for 30 min. Slides were incubated with antibodies at 4°C overnight,
and then the sections were incubated with goat anti-rabbit IgG conjugated
with horseradish peroxidase at room temperature for 60 min. After di-
aminobenzidine (DAB) staining, images were taken by Nikon and scored
blindly.
RT-PCR. Total RNA was extracted from cells using TRIzol reagent
(Invitrogen). cDNA was synthesized using the SuperScript First Strand
Synthesis kit (Invitrogen) from 0.5- to 1.0-g RNA samples. cDNA syn-
thesis was performed with the SuperScript III First-Strand Synthesis Sys-
tem according to the manufacturer’s instructions. Quantitative reverse
transcription-PCRs (RT-PCRs) were carried out using SYBR green PCR
master mix reagents on an ABI 7500 Fast real-time PCR system (Applied
Biosystems). Thermal cycling was conducted at 95°C for 30 s, followed by
40 cycles of amplification at 95°C for 5 s, 55°C for 30 s, and 72°C for 15 s.
The relative quantification of gene expression for each sample was ana-
lyzed by the threshold cycle (CT) method. The following primers were
used for amplification: for CDC6, 5=-TGGGCGATGACAACCTATGC-3=
and 5=-TGGCTAGTTCTCTTTTGCTAGGA-3=; for ESPL1, 5=-CCGCCT
TGAAGGAGTTCCTG-3= and 5=-GGGGTAGACACTAAGTAGCCAT-
3=; for MCM4, 5=-GACGTAGAGGCGAGGATTCC-3= and 5=-GAGTGC
CGTATGTCAGTGGT-3=; for POLE2, 5=-GAATGCAGTCAGTCTGTTG
ATGA-3= and 5=-AACCTATCACCGGAGGAGTAAAT-3=; and for 18S
rRNA, 5=-ACCTGGTTGATCCTGCCAGT-3= and 5=-CTGACCGGGTT
GGTTTTGAT-3=.
Coimmunoprecipitation assay. Cells were lysed with 400 l of ice-
cold hypotonic gentle lysis buffer (10 mM Tris-HCl [pH 7.5], 10 mM
NaCl, 2 mM EDTA, 0.5% Triton X-100, 1 protease inhibitor cocktail set
I [Calbiochem]) and incubated on ice for 10 min. After sonication, the
protein complexes were pulled down with anti-Flag M2 affinity gel
(Sigma), monoclonal antihemagglutinin (anti-HA)-agarose (Sigma), or
anti-E2F antibody (Santa Cruz).
ChIP assay. Vector control and ROR-expressing MDA-MB 231 cells
were cross-linked using formaldehyde for the chromatin immunopre-
cipitation (ChIP) assay. The ChIP assay was performed based on the
Upstate Biotechnology ChIP protocol, with a few modifications. After
formaldehyde cross-linking, nuclei were isolated with a nuclear isola-
tion kit (Sigma) and resuspended in ChIP lysis buffer (1% SDS, 10 mM
EDTA, 50 mM Tris-HCl [pH 8.0]) containing protease inhibitor cock-
tail. Protein-DNA complexes were immunoprecipitated as per the Up-
state protocol. Isolated DNA was then analyzed by RT-PCR using the
following primers: CDC6 promoter, 5=-ACTACAGCCAATCAGAAT
CGAGGC-3= and 5=-TCCTCTTCTTTCCACCTCCTCAGT-3=, and
POLE2 promoter, 5=-GGAGACCAAGCAGGGATCTT-3= and 5=-GCA
ACTTGAAGGCGGAGAG-3=.
GST pulldown assay. Full-length E2F1 gene and deletion mutants
(M1 to M5) were cloned into pGEX-4T-1 plasmid. Full-length ROR1,
the DBD (containing the DNA-binding domain and hinge domain), or
ligand-binding domain (LBD) was cloned into the pGEX-4T-1 plasmid.
Glutathione S-transferase (GST) fusion protein expression was induced
in Escherichia coli by 0.1 mM isopropyl--D-thiogalactopyranoside
(IPTG) at 19°C overnight. Bacteria were lysed in radioimmunoprecipita-
tion assay (RIPA) buffer (50 mM Tris, 150 mM NaCl, 0.5% sodium de-
oxycholate, 1% NP-40) with protease inhibitors and purified using Pierce
glutathione-agarose (Thermo Scientific). Purified GST-fused proteins
were confirmed by Coomassie staining. HEK293 FT cells were transfected
with pCDH1-ROR1-flag or pCDH1-E2F1-flag plasmid using FuGENE
HD transfection reagent (Promega). Cells were lysed in RIPA buffer with
protease inhibitors 36 h after transfection. For the pulldown assay, GST-
fused protein binding beads incubated with HEK293 FT cells at 4°C for 4
h and then washed with RIPA buffer three times for immunoblotting
analysis.
Flow cytometry analysis. Vector control and ROR-expressing
MDA-MB 231 cells were starved with serum for 24 h and then trypsinized
for flow cytometry analysis. shROR-expressing and vector control
HMT-3522 S1 cells were trypsinized for flow cytometry analysis after star-
vation with EGF for 24 h. Cells were washed with 5 ml of ice-cold PBS,
suspended in 500 l of PBS, and then immediately fixed with 5 ml of cold
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70% ethyl alcohol (EtOH). Fixed cells were incubated with 200 l of
propidium iodide solution (0.2 mg/ml) and 20 l of RNase (10 mg/ml) at
37°C for 45 min. Flow cytometry analysis was performed at the fluores-
cence-activated cell sorting (FACS) facility at the School of Medicine,
University of Kentucky.
Mammary fat pad clearance and mammary epithelium cell trans-
plantation. Primary mammary organoids were isolated from 6- to
7-week-old female FVB mice (Friend virus B-outbred colony of Swiss
mice) with collagenase-trypsin solution (0.2% trypsin, 0.2% collagenase
type IV, 5% fetal calf serum, 5 g/ml of insulin, and 50 g/ml of genta-
micin in 50 ml of DMEM–F-12) as previously described (45). The isolated
mammary organoids were infected with lentivirus containing shControl
or shROR before transplantation. Three-week-old female FVB mice
were anesthetized, and the inguinal fat pads were cleared by surgically
removing the developing mammary epithelium. A small pocket was
formed in the cleared fat pad and shControl-infected mammary or-
ganoids were placed in the pocket; shROR-infected mammary or-
ganoids were transplanted on the contralateral side using the same proce-
dure. Five weeks after surgery, the outgrowth of transplants was analyzed
by performing whole mounts.
Whole-mount staining of mammary glands. The fourth mammary
glands were freshly dissected, spread on a glass slide, and fixed in Carnoy’s
fixative (6 parts ethanol, 3 parts chloroform, and 1 part glacial acetic acid)
overnight. After being washed in 70% ethanol for 15 min, glands were
FIG 1 ROR inhibits cell proliferation and expression of the E2F1-targeted genes. (A) ROR expression was assessed by Western blotting in breast cancer cells
infected with lentivirus containing the ROR-expressing construct. (B) Cell proliferation in control and ROR-expressing breast cancer cells was analyzed by
EdU staining. Cells were cultured in 3D Matrigel. ROR expression inhibited cell proliferation in MDA-MB 157 and MDA-MB 231 cells (n  3; *, P 	 0.05; **,
P 	 0.01). (C) Control or ROR-expressing T4 cells or MDA-MB 231 cells were injected into the mammary fat pad in SCID mice. Restoring ROR expression
in T4 cells or MDA-MB 231 cells inhibited tumor growth (n  6; *, P 	 0.05; **, P 	 0.01). (D) Cell proliferation was examined by Ki67 staining in tumors formed
by control or ROR-expressing T4-2 and MDA-MB 231 cells. The bar graph shows the Ki67 positivity ratio (n  3; **, P 	 0.01). (E) Gene set enrichment analysis
(GSEA) identified the gene set “CELL CYCLE_KEGG” to be enriched among genes that show a reduced expression in ROR-expressing cells (P  0.094). (F)
GSEA analysis showed that the gene set “E2F1_Q6_01” had reduced expression in ROR-expressing breast cancer cells. (G) Heat map showing that E2F1 target
genes were downregulated in ROR-expressing breast cancer cells compared with control cells. (H) Cell cycle progression in control and ROR-expressing cells
was examined by flow cytometry analysis. The percentage of cells in G1 phase was significantly increased, while that of cells in S phase was significantly decreased
in ROR-expressing MDA-MB 231 cells (n  3; *, P 	 0.05). (I) The top portion shows silencing efficiency of shROR in S1 cells, examined by Western blotting.
The bottom portion shows cell proliferation in control and shROR-expressing S1 cells, analyzed by EdU staining. Cells were cultured in 3D Matrigel.
Knockdown of ROR expression increased cell proliferation in S1 cells (n  2; *, P 	 0.05). (J) Cell cycle progression was analyzed by flow cytometry in control
and ROR-silenced S1 cells. The percentage of cells in G1 phase was significantly decreased, while the percentages of cells in S phase and G2 phase were
significantly increased in ROR-silenced cells compared with control cells (n  3; *, P 	 0.05).
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rinsed in distilled water for 5 min and then stained in carmine alum stain
solution (0.2% [wt/vol] carmine, 0.5% [wt/vol] aluminum potassium sul-
fate) for several hours to overnight. Slides were washed with 70% ethanol,
followed by 95% and 100% ethanol. For long-term storage and photo-
graphic documentation, glands were cleared in xylene and mounted with
Cytoseal 60 (Thermo Scientific) mounting medium. Whole mounts were
photographed using a Nikon microscope.
Statistical analysis. Experiments were repeated at least three times.
Results were reported as means 
 standard errors of the means (SEM);
significance of difference was assessed by an independent Student t test. A
P value of 	0.05 represented statistical significance, and a P value of
	0.01 represented high statistical significance.
RESULTS
ROR inhibits cell proliferation and expression of the E2F1 tar-
get genes. We showed previously that downregulation of ROR in
breast cancer is associated with enhanced cell proliferation and
aggressive phenotypes of breast cancer cells in 3D culture (25).
Expression of ROR in T4-2 cells inhibits tumor growth, suggest-
ing that ROR may modulate cell proliferation (25). Introducing
exogenous ROR in breast cancer cell lines MDA-MB 157 and
MDA-MB 231 (Fig. 1A) significantly inhibited cell proliferation in
3D culture (Fig. 1B). Ki67 staining showed that expression of
ROR also inhibited tumor growth and suppressed proliferation
of breast cancer cells in vivo (Fig. 1C and D).
To understand how ROR inhibits cell proliferation, we per-
formed microarray analysis in control and ROR-expressing breast
cancer cells. Hundreds of genes were identified to be differentially
expressed between the control and the ROR-expressing cells. Inter-
estingly, most of these genes do not contain ROR response elements
in their regulatory regions, suggesting that ROR modulates their
expression indirectly. Using gene set enrichment analysis (GSEA), we
found that genes related to the KEGG cell cycle pathway (Fig. 1E) and
E2F1-targeted genes were downregulated in ROR-expressing breast
cancer cells (Fig. 1F and G). Flow cytometry analysis showed that
ectopic expression of ROR in MDA-MB 231 cells significantly in-
creased the number of cells at G0/G1 phase and reduced the number
of cells in S phase (Fig. 1H). Silencing ROR in nonmalignant S1 cells
inhibited cell proliferation (Fig. 1I) and reduced the percentage of
cells in G1 phase (P 	 0.05), while the number of cells in S phase and
G2 phase was significantly increased in ROR-silenced cells com-
pared to control cells (P 	 0.05) (Fig. 1J). These results suggest that
ROR inhibits cell proliferation by inducing G1/S arrest in mammary
epithelial cells.
To confirm that ROR inhibits E2F1-targeted genes, a couple
of genes that regulate cell cycle progression and DNA replication
were analyzed by RT-PCR. The results showed that mRNA levels
of CDC6 (P 	 0.01), ESPL1 (P 	 0.01), MCM4 (P 	 0.01), and
POLE2 (P 	 0.01) were significantly downregulated in ROR-
expressing MDA-MB 231 cells compared with control cells (P 	
0.01) (Fig. 2A). Similar results were also observed with MDA-MB
157 cells (Fig. 2A). Silencing ROR in S1 cells enhanced the ex-
pression of CDC6 (P 	 0.01), MCM4 (P 	 0.01), and POLE2 (P 	
0.05) (Fig. 2B). Eln, a gene that is not regulated by E2F1, was used
FIG 2 ROR inhibits expression of E2F1-targeted genes. (A) mRNA levels of E2F1-targeted genes CDC6, ESPL1, MCM4, and POLE2 in control and ROR-
expressing MDA-MB 231 cells and MDA-MB 157 cells were analyzed by real-time RT-PCR. Expression of these E2F1 target genes was significantly downregu-
lated in ROR-expressing MDA-MB 231 cells and MDA-MB 157 cells compared to control cells (n  4; *, P 	 0.05; **, P 	 0.01). (B) Real-time RT-PCR results
showed that mRNA levels of CDC6, ESPL1, MCM4, and POLE2 were upregulated in ROR knockdown S1 cells compared with shRNA control S1 cells (n  4;
*, P 	 0.05; **, P 	 0.01). (C) Luciferase analysis was performed for MDA-MB 231 cells that were stably transfected with control (ctrl-Luc) or E2F1 response
luciferase reporter vector (E2F1-Luc). ROR inhibited E2F1-driven reporter activity (n  3; **, P 	 0.01). (D) E2F1 protein levels in control and ROR-
expressing MDA-MB 231 cells were examined by Western blotting. (E and F) Chromatin immunoprecipitation results showed that overexpression of ROR
significantly inhibited binding of E2F1 to the promoter regions of CDC6 (E) and POLE2 (F). Levels of AcH3 and AcH4 in the promoter regions of CDC6 and
POLE2 were also reduced in ROR-expressing cells (n  3; *, P 	 0.05; **, P 	 0.01). The ChIP data were normalized to input DNA, and the results represent
the relative changes in ROR group compared to the control group.
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as a negative control in real-time RT-PCR (data not shown). To
examine whether ROR directly regulates E2F1 transcriptional
activity, luciferase assays were performed with MDA-MB 231 cells
that were stably transfected with the E2F1 response report vector
(E2F1-Luc). Introducing exogenous ROR significantly inhibited
the luciferase activity driven by E2F1 (P 	 0.01) (Fig. 2C). These
results indicate that ROR suppressed E2F1-regulated transcrip-
tion.
We found that ROR expression had little effect on E2F1 pro-
tein levels in MDA-MB 231 cells (Fig. 2D). To understand how
ROR inhibits E2F1 activity, we performed chromatin immuno-
precipitation experiments. The E2F1-chromatin complexes were
pulled down with anti-E2F1 antibody from the control and
ROR-expressing MDA-MB 231 cells. Enrichment of specific
DNA fragments was measured by quantitative PCR. Ectopic ex-
pression of ROR significantly inhibited binding of E2F1 to the
promoter regions of CDC6 (P 	 0.01) and POLE2 (P 	 0.05)
(Fig. 2E and F). Levels of acetylated histone H3 (AcH3) and H4
(AcH4) in the promoter regions of CDC6 and POLE2 were also
significantly reduced upon ROR expression (Fig. 2E and F).
Thus, ROR inhibits binding of E2F1 to the targeted genes and
suppresses E2F1-induced chromatin remodeling.
ROR binds to E2F1 through the heptad repeat and marked
box domain. During cell cycle progression, a number of coregu-
lators, such as pRb, Sp1, and KAP1, dynamically bind to E2F1 and
modulate its activity (36–38). We hypothesized that ROR sup-
presses E2F1 transcription factor activity through a similar mech-
anism. Coimmunoprecipitation experiments were performed to
determine whether ROR binds to E2F1 in epithelial cells. ROR
and/or HA-E2F1 vector was cotransfected in HEK293 cells, and
the protein complexes were immunoprecipitated by anti-HA an-
tibody. A significant amount of ROR was pulled down in the
HA-E2F1-expressing cells but not in the control cells, indicating
that ROR binds to E2F1 in HEK293 cells (Fig. 3A). The interac-
FIG 3 ROR binds to the heptad repeat and marked box region of E2F1. (A) ROR was coimmunoprecipitated with E2F1 in HEK293 cells. The cells were
transfected with ROR and/or E2F1 expression vectors. (B) ROR was coimmunoprecipitated with E2F1 in MDA-MB 231 cells. The cells were transfected with
ROR and/or E2F1 expression vectors. (C) Binding of endogenous ROR and E2F1 was detected in S1 cells by coimmunoprecipitation experiments. (D) Binding
of GST-tagged ROR to E2F1was detected by in vitro GST pulldown assays. DBD, DBD and hinge domain of ROR; LBD, LBD domain of ROR. The DBD and
hinge region interacted with E2F1. (E) Binding of GST-tagged E2F1 to ROR was detected by in vitro GST pulldown assays. Deletion of the heptad repeat and
marked box region (amino acid 195 to 317) of E2F1 significantly reduced binding of E2F1 to ROR.
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tion between ROR and E2F1 was confirmed in MDA-MB 231
cells (Fig. 3B). We also showed interaction between endogenous
ROR and E2F1 in S1 cells by coimmunoprecipitation using E2F1
antibody (Fig. 3C). In addition, confocal analysis showed that
ROR was partially colocalized with E2F1 in the nuclei of MDA-
MB 231 cells (data not shown).
ROR exhibits a typical nuclear receptor domain structure
consisting of three major domains: a DNA-binding domain
(DBD), hinge, and ligand-binding domain (LBD). To understand
which domain of ROR is required for E2F1 binding, we per-
formed an in vitro GST pulldown assay. The results showed that
the DBD-and-hinge region was able to interact with E2F1 (Fig.
3D). E2F1 contains a cyclin A-binding domain, helix-loop-helix
DNA-binding domain, heptad repeat, marked box, and transacti-
vation domain (Fig. 3E). To further map the regions in E2F1 in-
volved in ROR-E2F1complex formation, in vitro GST pulldown
assays were performed with a panel of GST-tagged E2F1 mutants.
We found that deletion of the heptad repeat and marked box
domain (amino acid 195 to 317) in E2F1 dramatically reduced the
ability of E2F1 to bind with ROR, indicating that this region is
required for ROR-E2F1 interaction. The heptad repeat domain
mediates the heterodimer formation of E2F1 and DP1. Interest-
ingly, binding of ROR had no effect on formation of E2F1-DP1
dimerization (Fig. 4A and B). The results of in vivo and in vitro
binding assays indicate that ROR directly interacts with E2F1 to
inhibit its activity, but how binding of ROR inhibits E2F1 tran-
scriptional activity remained to be determined.
ROR recruits HDAC1 to E2F1 and reduces its acetylation. It
has been shown that covalent modifications, such as acetylation,
regulate binding of E2F1 to chromatin and E2F1-dependent tran-
FIG 4 ROR reduces E2F1 acetylation by recruiting HDAC1. (A) Coimmunoprecipitation experiments were performed with HEK293 cells cotransfected with ROR,
Flag-tagged E2F1, and HA-tagged DP1. (B) A binding assay showed that binding of Flag-tagged DP1 to GST-tagged E2F1 was not inhibited by ROR. (C) Lysine
acetylation of endogenous E2F1 was inhibited by ROR in MDA-MB 231 cells. (D) ROR and E2F1 both interacted with HDAC1 and were examined by immuno-
precipitation experiments performed with HEK293 cells transfected with HDAC1, ROR, and E2F1. (E) A luciferase reporter assay showed that inhibition of HDAC1
activity (TSA treatment or knockdown of HDAC1 by shHDAC1-containing lentivirus) rescued E2F1 activity in ROR-expressing MDA-MB 231 cells (n  3; **, P 	
0.01). (F) Immunoprecipitation experiment results showed that knockdown of HDAC1 rescued E2F1 acetylation in ROR-expressing MDA-MB 231 cells. (G) EdU
staining results showed that silencing HDAC1 partially rescued cell proliferation in ROR-expressing MDA-MB 231 cells (n  3; *, P 	 0.05).
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scription (40, 41). To determine whether binding of ROR inhib-
its E2F1 activity through modulation of the covalent modifica-
tions, we checked the acetylation levels on endogenous E2F1
protein in the control and the ROR-expressing MDA-MB 231
cells using immunoprecipitation. ROR expression significantly
inhibited the lysine acetylation on E2F1 (Fig. 4C). Since HDACs
play a critical role in reducing protein acetylation (46, 47), we
asked whether ROR reduces E2F1 acetylation by recruiting
HDACs to the protein complexes. We examined interaction be-
tween ROR and endogenous HDAC1 in HEK293 cells using co-
immunoprecipitation, and the data showed that HDAC1 bound
to ROR (data not shown). To determine whether ROR recruits
HDAC1 to E2F1, coimmunoprecipitation experiments were per-
formed in HDAC1-, E2F1-, and/or ROR-expressing HEK293
cells. Expression of ROR dramatically enhanced interaction be-
tween HDAC1 and E2F1, whereas a weak association between
E2F1 and HDAC1 was detected in the absence of ROR (Fig. 4D).
These results indicate that ROR recruits HDAC1 to E2F1, which,
in turn, reduces acetylated lysine levels in E2F1.
To assess whether ROR inhibits E2F1 by recruiting HDAC1
to E2F1, we performed rescue experiments with MDA-MB 231
cells containing the E2F1-Luc reporter construct. Expression of
ROR significantly inhibits the luciferase activity in these cells
(Fig. 2C and 4E). Inhibiting HDAC1 with TSA or shRNA against
HDAC1 enhanced E2F1 transcription activity that was suppressed
by ROR (Fig. 4E). Furthermore, silencing HDAC1 partially res-
cued E2F1 acetylation (Fig. 4F) and cell proliferation (Fig. 4G) in
ROR-expressing MDA-MB 231 cells. These data indicate that
HDAC1 is required for the inhibitory activity of ROR on E2F1.
ROR reversely correlated with cell proliferation and E2F1
target gene expression in mammary glands. The terminal end
bud, a bulbous invasive structure at the tip of growing ducts
(48–50), has much higher cell proliferation than does the mature
duct (19, 20). This spatial regulation of cell proliferation plays
FIG 5 ROR levels are reversely correlated with cell proliferation and E2F1 target expression in mammary glands. (A) Heat map showing that E2F1-targeted
genes were activated in terminal end buds (TEBs) compared to mammary ducts (DUC). (B) ROR mRNA levels were lower in TEBs than in DUC (*, P 	 0.05).
(C) Quantification data showing that expression levels of E2F1 target genes were significantly reduced in terminal end buds (**, P 	 0.01). A bar graph represents
the sum of the mRNA levels of E2F1 target genes in the microarray data generated from ductal and TEB epithelial cells. In panels B and C, values on the y axis are
mRNA level (log2). (D) Immunohistochemistry analysis of ROR and Ki67 expression in mammary glands derived from 5-week-old female mice. Ki67-positive
cells are enriched in terminal end buds, while intensive ROR staining was detected in mammary ducts (scale bar, 20 m). (E) Expression of Ki67 was analyzed
in the mammary ducts and terminal end buds derived from transplanted mammary glands. The primary epithelial cells were infected with lentivirus containing
control shRNA or shROR constructs before the transplantation (scale bar, 40 m). (F) Bar graph showing the ratio of Ki67 cell in shControl and shROR-
expressing ductal structure and terminal end buds of mammary glands. Increased cell proliferation was detected in ROR knockdown mammary gland epithelial
cells compared with that in the control group (n  5; **, P 	 0.01). (G) Whole-mount staining of transplanted mammary glands harvested 5 weeks following
transplantation (scale bar, 400 m). (H) Quantification of whole-mount staining results showed that ROR-silenced mammary glands had increased side
branching (n  3; *, P 	 0.05).
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important roles in normal mammary branching morphogenesis.
To understand the roles of the ROR-E2F1 axis in spatial regula-
tion of cell proliferation in mammary tissue, we analyzed the ex-
pression of ROR and E2F1-targeted genes in a published mi-
croarray data set generated from mouse terminal end bud and
mature duct tissues (51). ROR mRNA levels were significantly
reduced in the terminal end buds compared to duct glands, while
expression of E2F1-targeted genes was significantly upregulated in
the terminal end bulb (Fig. 5A to C). Immunohistochemistry
analysis confirmed that ROR expression was reduced in terminal
end buds compared to ductal epithelial cells in mouse mammary
glands. There were more Ki67-positive cells in the terminal end
buds than in ducts (Fig. 5D), which is consistent with the previous
finding that cells in terminal end buds are highly proliferative (19,
20). A reverse correlation of ROR with cell proliferation and
expression of the E2F1 target genes in terminal end buds and
ductal epithelial cells suggests potential roles for ROR in regu-
lating mammary branching morphogenesis.
Next, we performed mammary gland transplant experiments
to examine the function of ROR in spatial regulation of cell pro-
liferation during branching morphogenesis. Primary mammary
organoids were isolated from FVB mice and infected with lentivi-
rus containing control shRNA or shROR. The infected mam-
mary gland organoids were transplanted into 3-week-old FVB
mice with cleared fat pads. Five weeks following transplantation,
the transplanted mammary glands were taken out for immuno-
histochemistry analysis and whole-mount staining. Ki67 staining
showed that knockdown of ROR significantly enhanced cell pro-
liferation in the ductal epithelial cells (Fig. 5E and F) but had little
effect on cell proliferation in the terminal end buds (Fig. 5E and
F). We also found that ROR-silenced mammary glands had in-
creased side branching (Fig. 5G and H), suggesting that ROR-
induced growth arrest is important for normal mammary branch
morphogenesis.
DISCUSSION
A function for ROR in regulating cell proliferation has been re-
ported previously (7, 25), but how ROR inhibits cell prolifera-
tion in normal tissue development and disease progression re-
mains unclear. In the present study, we found that ROR bound
to E2F1 as a cofactor and inhibited E2F1 activity by recruiting
HDAC1 to the ROR-E2F1 complex. These findings identify a
noncanonical pathway of ROR to suppress E2F1-targeted gene
and cell cycle progression.
Cross talk between E2F and other transcription factors has
been reported previously (52–56). For instance, interaction be-
tween aryl hydrocarbon receptor (AHR) and E2F1 has been de-
tected in mouse hepatoma cells, and binding of AHR suppresses
E2F1-mediated apoptosis by modulating E2F1 transcriptional ac-
tivity (54, 55, 57). We showed that binding of ROR reduced
acetylation levels on E2F1 and inhibits its DNA binding activity.
Lysine acetylation is an important posttranslational modification
that regulates E2F1 activity. It has been reported that lysine resi-
dues 117, 120, and 125 on E2F1 are acetylated by the acetyltrans-
ferase complex CBP/p/CAF and that the acetyl group can be re-
moved by HDAC proteins. Acetylation of E2F1 enhances its DNA
binding ability and increases protein stability (41). It has been
shown that Rb, mSin3B, Ebp1, and RbAp48 recruit class I HDACs
(HDAC 1, HDAC2, and HDAC3) to E2Fs and modulate E2F tar-
get gene expression (58–61). Our data showed that ROR en-
hanced interaction between E2F1 and HDAC1; reducing HDAC1
expression or inhibiting its activity rescued E2F1 activity sup-
pressed by ROR. However, microarray data showed that the ma-
jority, but not all, of E2F1-targeted genes are inhibited by ROR,
suggesting that some E2F1-targeted gene may be dominantly reg-
ulated by other transcription factors or epigenetically silenced.
These results identify a novel pathway by which nuclear receptor
modulates E2F1 transcriptional activity.
Cell proliferation is tightly regulated during branching mor-
phogenesis, a fundamental developmental process that shapes the
formation of mammary glands (21, 22). Steroid hormones, local
growth factors, and their receptors play important roles in mam-
mary gland branching morphogenesis. For example, deletion of
insulin-like growth factor I receptor in mammary epithelial cells
inhibits cell proliferation in terminal end buds and impairs mam-
mary branching morphogenesis in mice (19). We found that
ROR expression was reversely correlated with cell proliferation
in terminal end bud and mammary ducts, suggesting ROR as the
inhibitor of cell proliferation during branch morphogenesis. In
fact, knockdown of ROR increased E2F1 target gene expression
and cell proliferation in the mammary ducts and enhanced side
branching in the transplanted mammary gland. Therefore, in-
creased ROR expression in mammary ducts is crucial to main-
tain the ductal structure by inhibiting cell proliferation (Fig. 6). In
addition, it has been reported that Wnt signaling has been identi-
fied as a downstream target of progesterone to induce side-branch
morphogenesis (62, 63). ROR has been shown to bind to
-catenin and inhibits the Wnt pathway during colon cancer de-
velopment (7). Thus, the Wnt/-catenin pathway is also a poten-
tial target of ROR to regulate branching morphogenesis.
Uncontrolled cell proliferation is a hallmark of cancer devel-
opment and progression, and dysregulation of the pRB/E2F path-
way plays a critical role in the enhanced cell proliferation in cancer
tissue. Mutation or deletion of pRB has been detected in many
cancers (64–67). However, it has been shown that in human breast
cancer patients, only about 20 to 30% of breast tumors are pRB
FIG 6 ROR suppresses E2F1 transcriptional activity by enhancing HDAC1-
E2F1 interaction in ductal epithelial cells during mammary gland morphogen-
esis.
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deficient and less than 10% of tumors show inactivated or mu-
tated pRB (64, 65). These results suggest that other proteins or
pathways inhibit expression or activation of E2F1 during breast
cancer development. Our previous study shows that 70% of hu-
man breast cancers have reduced ROR expression (25). Ectopic
expression of ROR in breast cancer cells reduces cell prolifera-
tion and inhibits and tumor growth. Thus, aberrant activation of
the E2F1 pathway and cell cycle progression in breast cancer are at
least partially due to reduced ROR expression. Further investi-
gation of the connection of ROR with E2F1 activation and cell
proliferation in breast cancer tissue may lead to discovery of a
potential pathway to inhibit breast cancer progression.
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